{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:23:10Z","timestamp":1792174990967,"version":"4.4.0"},"reference-count":134,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Laboratories Excellence Program","award":["National Tumorbiology Laboratory project (NLP-17)"],"award-info":[{"award-number":["National Tumorbiology Laboratory project (NLP-17)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pheochromocytomas and paragangliomas are the most heritable endocrine tumors. In addition to the inherited mutation other driver mutations have also been identified in tumor tissues. All these genetic alterations are clustered in distinct groups which determine the pathomechanisms. Most of these tumors are benign and their surgical removal will resolve patient management. However, 5\u201315% of them are malignant and therapeutical possibilities for them are limited. This review provides a brief insight about the tumorigenesis associated with pheochromocytomas\/paragangliomas in order to present them as potential therapeutical targets.<\/jats:p>","DOI":"10.3390\/ijms23031450","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:00:56Z","timestamp":1643320856000},"page":"1450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach"],"prefix":"10.3390","volume":"23","author":[{"given":"Balazs","family":"Sarkadi","sequence":"first","affiliation":[{"name":"ELKH Hereditary Cancer Research Group, 1052 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8576","authenticated-orcid":false,"given":"Eva","family":"Saskoi","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, National Institute of Oncology, 1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-409X","authenticated-orcid":false,"given":"Henriett","family":"Butz","sequence":"additional","affiliation":[{"name":"ELKH Hereditary Cancer Research Group, 1052 Budapest, Hungary"},{"name":"Department of Molecular Genetics, National Institute of Oncology, 1122 Budapest, Hungary"},{"name":"Department of Laboratory Medicine, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-674X","authenticated-orcid":false,"given":"Attila","family":"Patocs","sequence":"additional","affiliation":[{"name":"ELKH Hereditary Cancer Research Group, 1052 Budapest, Hungary"},{"name":"Department of Molecular Genetics, National Institute of Oncology, 1122 Budapest, Hungary"},{"name":"Department of Laboratory Medicine, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-018-4181-2","article-title":"Pheochromocytoma and paraganglioma\u2014an update on diagnosis, evaluation, and management","volume":"35","author":"Jain","year":"2020","journal-title":"Pediatric Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: Why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Feng","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"L51-l55","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and\/or Unresectable Pheochromocytoma and Paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: A systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study","volume":"104","author":"Hescot","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-1500","DOI":"10.12688\/f1000research.14568.1","article-title":"New insights on the pathogenesis of paraganglioma and pheochromocytoma","volume":"7","author":"Kantorovich","year":"2018","journal-title":"F1000Res"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"T201","DOI":"10.1530\/ERC-18-0085","article-title":"65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma","volume":"25","author":"Neumann","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: A cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"T71","DOI":"10.1530\/ERC-15-0226","article-title":"15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations","volume":"22","author":"Baysal","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.beem.2010.04.001","article-title":"SDH-related pheochromocytoma and paraganglioma","volume":"24","author":"Kantorovich","year":"2010","journal-title":"Best Pr. Res. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1590\/2359-3997000000299","article-title":"The clinical genetics of phaeochromocytoma and paraganglioma","volume":"61","author":"Grossman","year":"2017","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1\u20135","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_24","first-page":"130","article-title":"Germline SUCLG2 Variants in Patients with Pheochromocytoma and Paraganglioma","volume":"114","author":"Pang","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Buffet","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Cascon","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1158\/1078-0432.CCR-16-2250","article-title":"Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas","volume":"23","author":"Remacha","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","article-title":"Germline Mutations in the Mitochondrial 2-Oxoglutarate\/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas","volume":"78","author":"Buffet","year":"2018","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.celrep.2019.01.106","article-title":"HIF1\u03b1 Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis","volume":"26","author":"Urrutia","year":"2019","journal-title":"Cell Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajhg.2019.02.017","article-title":"Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas","volume":"104","author":"Remacha","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/jc.2009-1479","article-title":"Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome","volume":"94","author":"Gaal","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/jhh.2012.20","article-title":"An update on the genetics of pheochromocytoma","volume":"27","author":"Karasek","year":"2013","journal-title":"J. Hum. Hypertens"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1126\/science.7824936","article-title":"Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B","volume":"267","author":"Santoro","year":"1995","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/MCB.15.3.1613","article-title":"Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations","volume":"15","author":"Asai","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19297","DOI":"10.1074\/jbc.M905866199","article-title":"Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells","volume":"275","author":"Califano","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1074\/jbc.275.5.3568","article-title":"Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase\/AKT signaling pathway","volume":"275","author":"Billaud","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: Management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"ref_42","first-page":"755","article-title":"Multiple endocrine neoplasia type 2: An overview","volume":"13","author":"Moline","year":"2011","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"ref_43","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., and Amemiya, A. (1993). Multiple Endocrine Neoplasia Type 2. GeneReviews(\u00ae), University of Washington."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","article-title":"Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas","volume":"22","author":"Toledo","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-12-1451","article-title":"Molecular pathways: MERTK signaling in cancer","volume":"19","author":"Cummings","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_46","first-page":"647","article-title":"Cloning and mRNA expression analysis of a novel human protooncogene, c-mer","volume":"5","author":"Graham","year":"1994","journal-title":"Cell Growth Differ."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/onc.2015.172","article-title":"Rethinking pheochromocytomas and paragangliomas from a genomic perspective","volume":"35","author":"Favier","year":"2016","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","article-title":"The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins","volume":"63","author":"Ballester","year":"1990","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.2134734","article-title":"Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients","volume":"249","author":"Wallace","year":"1990","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-11-3891","article-title":"MAX and MYC: A heritable breakup","volume":"72","author":"Robledo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1101\/gad.6.1.71","article-title":"Myc and Max associate in vivo","volume":"6","author":"Blackwood","year":"1992","journal-title":"Genes Dev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1677\/erc.1.00838","article-title":"Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: Activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/hmg\/ddy095","article-title":"The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex","volume":"27","author":"Deng","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2010.1830","article-title":"Spectrum and Prevalence of FP\/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas","volume":"304","author":"Yao","year":"2010","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E308","DOI":"10.1210\/jc.2014-2473","article-title":"Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation","volume":"100","author":"Toledo","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","article-title":"Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma","volume":"99","author":"Welander","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1530\/EC-20-0460","article-title":"Genetic predisposition to neural crest-derived tumors: Revisiting the role of KIF1B","volume":"9","author":"Leteurtre","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Bernal","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J. Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1210\/jc.2009-2170","article-title":"Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas","volume":"95","author":"Gaal","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jmedgenet-2018-105714","article-title":"Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma","volume":"56","author":"Pigny","year":"2019","journal-title":"J. Med. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/jmedgenet-2015-103218","article-title":"Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients","volume":"52","author":"Mancikova","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"E1376","DOI":"10.1210\/jc.2013-3879","article-title":"H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series","volume":"99","author":"Oudijk","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/gcc.22347","article-title":"HRAS mutation prevalence and associated expression patterns in pheochromocytoma","volume":"55","author":"Stenman","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"138573","DOI":"10.1155\/2015\/138573","article-title":"Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis","volume":"2015","author":"Luchetti","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Burnichon","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ecl.2017.01.009","article-title":"Genetics of Pheochromocytomas and Paragangliomas: An Overview on the Recently Implicated Genes MERTK, MET, Fibroblast Growth Factor Receptor 1, and H3F3A","volume":"46","author":"Toledo","year":"2017","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1541-7786.MCR-20-0992","article-title":"Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression","volume":"19","author":"Alzofon","year":"2021","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12964-019-0496-2","article-title":"The role of CSDE1 in translational reprogramming and human diseases","volume":"18","author":"Guo","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S0016672320000038","article-title":"Germline variant in REXO2 is a novel candidate gene in familial pheochromocytoma","volume":"102","author":"Laitman","year":"2020","journal-title":"Genet. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ijc.29957","article-title":"Malignant pheochromocytomas\/paragangliomas harbor mutations in transport and cell adhesion genes","volume":"138","author":"Rehammar","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tomi\u0107, T.T., Olausson, J., Rehammar, A., Deland, L., Muth, A., Ejesk\u00e4r, K., Nilsson, S., Kristiansson, E., Wass\u00e9n, O.N., and Abel, F. (2020). MYO5B mutations in pheochromocytoma\/paraganglioma promote cancer progression. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1008803"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Me\u0161kyt\u0117, E.M., Keskas, S., and Ciribilli, Y. (2020). MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207710"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/gcc.22267","article-title":"Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene","volume":"54","author":"Juhlin","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Robledo","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1210\/jc.2013-2600","article-title":"Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome","volume":"99","author":"Buffet","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fendo.2018.00515","article-title":"Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging","volume":"9","author":"Alrezk","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.2147\/OTT.S219056","article-title":"Therapies targeting the signal pathways of pheochromocytoma and paraganglioma","volume":"12","author":"Liu","year":"2019","journal-title":"Onco Targets"},{"key":"ref_85","first-page":"769","article-title":"The systems of metastatic potential prediction in pheochromocytoma and paraganglioma","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Schiavi","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kimura, N., Takekoshi, K., and Naruse, M. (2018). Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine. J. Clin. Med., 7.","DOI":"10.20944\/preprints201807.0478.v1"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1530\/ERC-14-0016","article-title":"The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors","volume":"21","author":"Liu","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-17-0306","article-title":"TERT structural rearrangements in metastatic pheochromocytomas","volume":"25","author":"Dwight","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Flores, S.K., Estrada-Zuniga, C.M., Thallapureddy, K., Armaiz-Pe\u00f1a, G., and Dahia, P.L.M. (2021). Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers. Cancers, 13.","DOI":"10.3390\/cancers13184602"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: From genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cen.14375","article-title":"PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era","volume":"95","author":"Ryder","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_95","first-page":"1","article-title":"Personalized Management of Pheochromocytoma and Paraganglioma","volume":"20","author":"Bechmann","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Hicks","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"15879","DOI":"10.1073\/pnas.0907843106","article-title":"Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues","volume":"106","author":"Ziegler","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/02841860701441848","article-title":"Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours","volume":"46","author":"Krenning","year":"2007","journal-title":"Acta. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Jha","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"39","author":"Timmers","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fonc.2019.00053","article-title":"Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma","volume":"9","author":"Jha","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_103","first-page":"46","article-title":"Superiority of 68Ga-DOTATATE PET\/CT to other functional and anatomic imaging modalities in the detection of SDHD-related pheochromocytoma and paraganglioma\u2014A comparative prospective study","volume":"59","author":"Jha","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT\/MRI","volume":"57","author":"Janssen","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.tem.2017.08.001","article-title":"New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma","volume":"28","author":"Pacak","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma\/Pheochromocytoma","volume":"94","author":"Joshua","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/ERC-16-0231","article-title":"Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome","volume":"23","author":"Nambuba","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2967\/jnumed.116.187690","article-title":"Functional Imaging Signature of Patients Presenting with Polycythemia\/Paraganglioma Syndromes","volume":"58","author":"Janssen","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: A multicenter prospective study from the PGL.EVA Investigators","volume":"98","author":"Houzard","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-06-0712","article-title":"The role of 6-[18F] fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome","volume":"156","author":"Kaji","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12149-017-1162-7","article-title":"Compared to (123)I-MIBG SPECT\/CT, (18)F-DOPA PET\/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma","volume":"31","author":"Kroiss","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2967\/jnumed.115.154815","article-title":"Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters","volume":"56","author":"Rao","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1158\/1078-0432.CCR-19-2335","article-title":"Therapeutic Targeting of SDHB-Mutated Pheochromocytoma\/Paraganglioma with Pharmacologic Ascorbic Acid","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1210\/jc.2014-2138","article-title":"Genotype-Specific Differences in the Tumor Metabolite Profile of Pheochromocytoma and Paraganglioma Using Untargeted and Targeted Metabolomics","volume":"100","author":"Rao","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.1038\/ncomms9784","article-title":"Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism","volume":"6","author":"Hollinshead","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Sarkadi, B., Meszaros, K., Krencz, I., Canu, L., Krokker, L., Zakarias, S., Barna, G., Sebestyen, A., Papay, J., and Hujber, Z. (2020). Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas\/Paragangliomas. Cancers, 12.","DOI":"10.1530\/endoabs.70.OC1.1"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"28922","DOI":"10.18632\/oncotarget.15959","article-title":"Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors","volume":"8","author":"Kitazawa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"8850990","DOI":"10.1155\/2021\/8850990","article-title":"Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas","volume":"2021","author":"Kim","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ymben.2016.11.005","article-title":"Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors","volume":"43","author":"Lorendeau","year":"2017","journal-title":"Metab. Eng."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Subbiah, V., Stephen, B., Ma, J., Milton, D., Xu, M., Zarifa, A., Akhmedzhanov, F.O., Tsimberidou, A., and Habra, M.A. (2020). Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers, 12.","DOI":"10.3390\/cancers12082307"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","article-title":"Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas","volume":"46","author":"Elston","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA\u2013Conjugated Somatostatin Receptor\u2013Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Vyakaranam, A.R., Crona, J., Norl\u00e9n, O., Granberg, D., Garske-Rom\u00e1n, U., Sandstr\u00f6m, M., Fr\u00f6ss-Baron, K., Thiis-Evensen, E., Hellman, P., and Sundin, A. (2019). Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE. Cancers, 11.","DOI":"10.3390\/cancers11070909"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Pang, Y., Liu, Y., Pacak, K., and Yang, C. (2019). Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 11.","DOI":"10.3390\/cancers11040436"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:51Z","timestamp":1760134131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":134,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23031450"],"URL":"https:\/\/doi.org\/10.3390\/ijms23031450","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}